Close Search X

Oncotype DX Breast Recurrence Score

NICE expands recommendation for the Oncotype DX test to more patients with early-stage breast cancer

Know with confidence who will benefit from chemotherapy and who will not1-4

The National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its updated guidance once again recommending the Oncotype DX Breast Recurrence Score test for use in clinical practice to guide adjuvant chemotherapy treatment decisions for certain patients with early-stage breast cancer. Furthermore, NICE expanded the recommendation to now also include patients with micro metastases, indicating that some cancer cells have spread to the lymph nodes.


Order the test


The recommendation of the Oncotype DX test in this updated guidance is based on its unique ability to predict who will benefit from chemotherapy and who will not. NICE acknowledges that Oncotype DX is:

  • the only test to overall reduce the number of patients who receive chemotherapy
  • the only test supported by long-term patient outcomes evidence, including the TAILORx study
  • and the most cost-effective tool to guide chemotherapy treatment.

The Oncotype DX assay is incorporated in major clinical guidelines

 

ASCO
 

NCCN
 

St. Gallen
 

ESMO
 

NICE

FOR YOUR PATIENTS WITH HR+, HER2–, NODE-NEGATIVE, EARLY-STAGE, INVASIVE BREAST CANCER

The Oncotype DX Breast Recurrence Score test provides clarity for adjuvant treatment decisions


Learn more about the test
REFERENCES

  1. Sparano et al. N Engl J Med. 2015.
  2. Sparano et al. N Engl J Med. 2018.
  3. Sparano et al. ASCO 2018
  4. Paik et al. J Clin Oncol. 2006

American Society of Clinical Oncology (ASCO) and ASCO are registered trademarks of ASCO; National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. ESMO is a trademark of European Society of Medical Oncology. NICE, ASCO, NCCN, ESMO and St. Gallen do not endorse any product of therapy.

Contact Us

 Get in Touch
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, and Oncotype DX Genomic Prostate Score are registered trademarks, and "Making cancer care smarter," GPS, and AR-V7 Nucleus Detect are pending registered trademarks, of Genomic Health, Inc.
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.